Furthermore, ARL4C exhibited a positive association with immunostimulatory checkpoint markers in most cancer types, and a negative association observed with TNFRSF14 in BLCA, CHOL, ESCA, KIRC, OV, PCPG, READ, SKCM, and UCEC (Figure 7B). Here, ARL4C is linked to bladder transitional cell carcinoma.